Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group

Antonio Bertolotto, Marco Capobianco, Maria Pia Amato, Elisabetta Capello, Ruggero Capra, Diego Centonze, Maria Di Ioia, Antonio Gallo, Luigi Grimaldi, Luisa Imberti, Alessandra Lugaresi, Chiara Mancinelli, Maria Giovanna Marrosu, Lucia Moiola, Enrico Montanari, Silvia Romano, Luigina Musu, Damiano Paolicelli, Francesco Patti, Carlo PozzilliSilvia Rossi, Marco Salvetti, Gioachino Tedeschi, Maria Rosaria Tola, Maria Troiano, Mauro Zaffaroni, Simona Malucchi

Research output: Contribution to journalArticle

Abstract

Interferon beta (IFNβ) was the first specific disease-modifying treatment licensed for relapsing-remitting multiple sclerosis, and is still one of the most commonly prescribed treatments. A strong body of evidence supports the effectiveness of IFNβ preparations in reducing the annual relapse rate, magnetic resonance (MRI) disease activity and disease progression. However, the development of binding/neutralizing antibodies (BAbs/NAbs) during treatment negatively affects clinical and MRI outcomes. Therefore, guidelines for the clinical use for the detection of NAbs in MS may result in better treatment of these patients. In October 2012, a panel of Italian neurologists from 17 MS clinics convened in Milan to review and discuss data on NAbs and their clinical relevance in the treatment of MS. In this paper, we report the panel's recommendations for the use of IFNβ Nabs detection in the early identification of IFNβ non-responsiveness and the management of patients on IFNβ treatment in Italy, according to a model of therapeutically appropriate care.

Original languageEnglish
Pages (from-to)307-316
Number of pages10
JournalNeurological Sciences
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • Guidelines
  • IFNβ
  • Immunogenicity
  • Multiple sclerosis
  • Neutralizing antibodies

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint Dive into the research topics of 'Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group'. Together they form a unique fingerprint.

  • Cite this

    Bertolotto, A., Capobianco, M., Amato, M. P., Capello, E., Capra, R., Centonze, D., Di Ioia, M., Gallo, A., Grimaldi, L., Imberti, L., Lugaresi, A., Mancinelli, C., Marrosu, M. G., Moiola, L., Montanari, E., Romano, S., Musu, L., Paolicelli, D., Patti, F., ... Malucchi, S. (2014). Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: Report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 35(2), 307-316. https://doi.org/10.1007/s10072-013-1616-1